| The tumour microenvironment in pancreatic cancer—clinical challenges and opportunities WJ Ho, EM Jaffee, L Zheng Nature reviews Clinical oncology 17 (9), 527-540, 2020 | 946 | 2020 |
| Programmed cell death ligand-1 (PD-L1) and CD8 expression profiling identify an immunologic subtype of pancreatic ductal adenocarcinomas with favorable survival L Danilova, WJ Ho, Q Zhu, T Vithayathil, A De Jesus-Acosta, NS Azad, ... Cancer immunology research 7 (6), 886-895, 2019 | 213 | 2019 |
| Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity. WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature cancer 2 (9), 891-903, 2021 | 181 | 2021 |
| Incorporation of multicellular spheroids into 3‐D polymeric scaffolds provides an improved tumor model for screening anticancer drugs WJ Ho, EA Pham, JW Kim, CW Ng, JH Kim, DT Kamei, BM Wu Cancer science 101 (12), 2637-2643, 2010 | 153 | 2010 |
| A phase II study of allogeneic GM-CSF–transfected pancreatic tumor vaccine (GVAX) with ipilimumab as maintenance treatment for metastatic pancreatic cancer AA Wu, KM Bever, WJ Ho, EJ Fertig, N Niu, L Zheng, RM Parkinson, ... Clinical cancer research 26 (19), 5129-5139, 2020 | 111 | 2020 |
| Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas WJ Ho, M Yarchoan, A Hopkins, R Mehra, S Grossman, H Kang Journal for immunotherapy of cancer 6, 1-8, 2018 | 110 | 2018 |
| The role of the 3D environment in hypoxia-induced drug and apoptosis resistance JW Kim, WJ Ho, BM Wu Anticancer research 31 (10), 3237-3245, 2011 | 109 | 2011 |
| Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities I Christodoulou, WJ Ho, A Marple, JW Ravich, A Tam, R Rahnama, ... Journal for immunotherapy of cancer 9 (12), e003894, 2021 | 106 | 2021 |
| From bench to bedside: Single-cell analysis for cancer immunotherapy EF Davis-Marcisak, A Deshpande, GL Stein-O’Brien, WJ Ho, D Laheru, ... Cancer cell 39 (8), 1062-1080, 2021 | 90 | 2021 |
| Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature Cancer 2 (9), 891-903, 2021 | 75 | 2021 |
| Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes A Balaji, J Zhang, B Wills, KA Marrone, H Elmariah, M Yarchoan, ... Journal of oncology practice 15 (9), e825-e834, 2019 | 57 | 2019 |
| Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma WJ Ho, L Danilova, SJ Lim, R Verma, S Xavier, JM Leatherman, ... Journal for immunotherapy of cancer 8 (1), e000394, 2020 | 49 | 2020 |
| Multi-scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma H Mi, WJ Ho, M Yarchoan, AS Popel Frontiers in Immunology, 1986, 2022 | 43 | 2022 |
| Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways WJ Ho, R Erbe, L Danilova, Z Phyo, E Bigelow, G Stein-O’Brien, ... Genome biology 22 (1), 154, 2021 | 42 | 2021 |
| Systemic inhibition of PTPN22 augments anticancer immunity WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ... The Journal of clinical investigation 131 (17), 2021 | 40 | 2021 |
| Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments DJ Zabransky, L Danilova, JM Leatherman, TY Lopez‐Vidal, J Sanchez, ... Hepatology 77 (5), 1566-1579, 2023 | 39 | 2023 |
| Effects of B cell–activating factor on tumor immunity M Yarchoan, WJ Ho, A Mohan, Y Shah, T Vithayathil, J Leatherman, ... JCI insight 5 (10), e136417, 2020 | 37 | 2020 |
| Antioxidant micronutrients and the risk of renal cell carcinoma in the Women's Health Initiative cohort WJ Ho, MS Simon, VO Yildiz, JM Shikany, I Kato, JL Beebe‐Dimmer, ... Cancer 121 (4), 580-588, 2015 | 34 | 2015 |
| Understanding the diagnostic yield of current endoscopic biopsy for gastric neoplasm: A prospective single-center analysis based on tumor characteristics stratified by biopsy … WG Kwack, WJ Ho, JH Kim, JH Lee, EJ Kim, HW Kang, JK Lee Medicine 95 (30), e4196, 2016 | 33 | 2016 |
| Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model RJ Sové, BK Verma, H Wang, WJ Ho, M Yarchoan, AS Popel Journal for immunotherapy of cancer 10 (11), e005414, 2022 | 30 | 2022 |
Mark YarchoanJohns HopkinsEmail verificata su jhmi.edu